# ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/ADMA/adma-biologics-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update
Ticker: ADMA
Company: ADMA Biologics
Source: ADMA Biologics
Published: 2026-02-25 21:05 EST
Original Source URL: https://ir.admabiologics.com
## Summary

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income ( 1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA ( 2) of $231 Million,

## Article Body
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income ( 1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA ( 2) of $231 Million,
## Recent Company News
- 2026-05-06 20:05 EST — [ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADMA/adma-biologics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: ADMA Biologics
- 2026-05-04 11:00 EST — [ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older](https://biopharmsignal.com/news/ADMA/adma-biologics-announces-fda-approval-to-expand-the-label-for-ascenivtm-to-include-pediatric-immune-compromised-patients-two-years-of-age-and-older) — Source: ADMA Biologics
- 2026-04-29 11:00 EST — [ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026](https://biopharmsignal.com/news/ADMA/adma-biologics-to-report-first-quarter-2026-financial-results-on-may-6-2026) — Source: ADMA Biologics
- 2026-03-27 11:00 EST — [ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research](https://biopharmsignal.com/news/ADMA/adma-biologics-issues-statement-refuting-unsubstantiated-misleading-and-inaccurate-allegations-by-culper-research) — Source: ADMA Biologics
- 2026-03-25 10:30 EST — [ADMA Biologics Addresses Misleading Short-Seller Report](https://biopharmsignal.com/news/ADMA/adma-biologics-addresses-misleading-short-seller-report) — Source: ADMA Biologics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)